Current oral agents for type 2 diabetes
- 1 May 2002
- journal article
- review article
- Published by Informa UK Limited in Postgraduate Medicine
- Vol. 111 (5), 32-46
- https://doi.org/10.3810/pgm.2002.05.1194
Abstract
Increasingly, type 2 diabetes takes a toll on public health and healthcare costs in the United States. Although the remedy for this growing problem is very complex, two critical components of its control are prevention and effective therapy. Progress in diabetes prevention is likely to take decades. But fortunately, growth in our understanding of what occurs in this chronic disease has led to advances in the pharmacologic options aimed at decreasing hyperglycemia, the main clinically measurable metabolic consequence of diabetes. In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect.Keywords
This publication has 20 references indexed in Scilit:
- Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.Diabetes Care, 2000
- Diabetes trends in the U.S.: 1990-1998.Diabetes Care, 2000
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Pharmacologic Therapy for Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999
- A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.Diabetes Care, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Economic Consequences of Diabetes Mellitus in the U.S. in 1997Diabetes Care, 1998
- ALPHA-GLUCOSIDASE INHIBITORSEndocrinology and Metabolism Clinics of North America, 1997
- SULFONYLUREASEndocrinology and Metabolism Clinics of North America, 1997
- Non-Insulin-Dependent Diabetes Mellitus — A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin ResistanceNew England Journal of Medicine, 1996